Přehled o publikaci
2024
Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules
ABRAMENKO, Nikita, Frederic VELLIEUX, Katerina VESELA, Zdenek KEJIK, Jan HAJDUCH et. al.Základní údaje
Originální název
Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules
Autoři
ABRAMENKO, Nikita, Frederic VELLIEUX, Katerina VESELA, Zdenek KEJIK, Jan HAJDUCH, Michal MASAŘÍK, Petr BABULA, David HOSKOVEC, Karel PACAK, Pavel MARTASEK, Karel SMETANA a Milan JAKUBEK
Vydání
Scientific Reports, London, Nature Publishing Group, 2024, 2045-2322
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Organizace
Lékařská fakulta – Masarykova univerzita – Repozitář
UT WoS
001158746700029
EID Scopus
2-s2.0-85184437842
Klíčová slova anglicky
estrogen receptor modulators; immune checkpoint molecules
Návaznosti
LM2023053, projekt VaV. LX22NPO5102, projekt VaV. LX22NPO5107, projekt VaV. NU21-08-00407, projekt VaV.
Změněno: 6. 6. 2024 04:52, RNDr. Daniel Jakubík
Anotace
V originále
Immune checkpoints regulate the immune system response. Recent studies suggest that flavonoids, known as phytoestrogens, may inhibit the PD-1/PD-L1 axis. We explored the potential of estrogens and 17 Selective Estrogen Receptor Modulators (SERMs) as inhibiting ligands for immune checkpoint proteins (CTLA-4, PD-L1, PD-1, and CD80). Our docking studies revealed strong binding energy values for quinestrol, quercetin, and bazedoxifene, indicating their potential to inhibit PD-1 and CTLA-4. Quercetin and bazedoxifene, known to modulate EGFR and IL-6R alongside estrogen receptors, can influence the immune checkpoint functionality. We discuss the impact of SERMs on PD-1 and CTLA-4, suggesting that these SERMs could have therapeutic effects through immune checkpoint inhibition. This study highlights the potential of SERMs as inhibitory ligands for immune checkpoint proteins, emphasizing the importance of considering PD-1 and CTLA-4 inhibition when evaluating SERMs as therapeutic agents. Our findings open new avenues for cancer immunotherapy by exploring the interaction between various SERMs and immune checkpoint pathways.